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Summary 
RING and U-box ubiquitin ligases promote ubiquitin (Ub) transfer by priming Ub-
conjugated E2 in a closed conformation to optimize the thioester bond for 
nucleophilic attack by substrate lysine. Here, we describe a single-turnover lysine 
discharge assay for direct assessment of the activity of any RING/U-box E3-E2~Ub 
complex. 
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1. Introduction 
Ubiquitination is a post-translational modification whereby the small 76 amino acid 
protein modifier ubiquitin (Ub) is covalently attached to a protein substrate [1]. 
Ubiquitination is achieved by the sequential actions of three enzymes: Ub-activating 
enzyme (E1), a Ub-conjugating enzyme (E2) and a Ub ligase (E3) [2, 3]. Initially, E1 
activates Ub in a Mg2+-ATP-dependent manner and a thioester bond is formed 
between the catalytic cysteine of E1 and the diglycine motif at the C-terminus of Ub 
to produce E1~Ub complex, where ~ denotes a thioester (Fig. 1a). E1~Ub 
subsequently recruits an E2, and Ub is transferred to the active site cysteine of E2 via 
its tail, thereby forming an E2~Ub intermediate (Fig. 1b). Next, an E3 recruits E2~Ub 
and substrate to mediate the transfer of Ub to substrate (Fig. 1c). In this final step, an 
isopeptide/amide link is formed between the Gly 76 of Ub and a free amino group 
from a lysine side chain or the N-terminus of a substrate protein (Fig. 1d).  
[INSERT FIGURE 1 NEAR HERE] 
 
The human genome encodes two E1s, approximately 40 E2s and over 600 putative 
E3s [4]. E3s are categorized into three families based on their Ub transfer mechanism: 
HECT, RING-between-RING (RBR), and RING/U-box [5]. HECT and RBR E3s 
form an E3~Ub complex prior to transferring Ub to substrate whereas RING/U-box 
E3s catalyze the transfer of Ub directly from E2~Ub to substrate (Fig. 1e). A shared 
feature among all RING/U-box E3s is the presence of a RING or U-box domain that 
recruits E2~Ub and promotes Ub transfer. Simple RING/U-box E3s encode a 
RING/U-box domain and substrate-binding domain within a single polypeptide chain 
whereas multisubunit E3s like cullin RING ligases encode these domains on multiple 
polypeptide chains. Some simple RING E3s like RNF38 function as monomers, but 
others, like XIAP or BRCA1/BARD, are only functional as dimers [5].  
 
Although binding is observed for many E2-E3 pairs in vitro, this does not always 
translate to function. For example, BRCA1/BARD binds the E2 UbcH7 [6] but does 
not enhance its reactivity [7]. E2s have an intrinsic reactivity that generally involves 
Ub transfer to a thiol as in a cysteine residue or to an amine as in a lysine residue or 
the N-terminus of a protein [8]. Based on these properties, it is essential to select an 
E2 for lysine discharge assays that has intrinsic reactivity toward lysine. Some E2s, 
like UbcH7, are only reactive toward cysteine [7] whereas others, like Ube2W, only 
react with the N-terminal amino group of a protein or peptide [9, 10, 11].  
 
The chemical reaction profile of RING/U-box mediated Ub transfer involves a 
number of steps with several species of intermediates. Initially, both E2~Ub and a 
protein substrate are recruited to form a RING/U-box-substrate-E2~Ub complex (Fig. 
2a). The substrate lysine side chain or N-terminal amino group is then deprotonated to 
produce a nucleophile (Fig. 2b). This activated nucleophile subsequently attacks the 
carbonyl group of the E2~Ub thioester to form an oxyanion intermediate in which E2 
is covalently linked to both Ub and substrate (Fig. 2c). In the final steps, a thiol group 
is eliminated (Fig. 2d and 2e), thereby forming an amide/isopeptide bond between 
substrate and ubiquitin (Fig. 2f).  
[INSERT FIGURE 2 NEAR HERE] 
 
To promote Ub transfer, RING/U-box E3s bring E2~Ub together with substrate and 
optimize the orientation of the E2~Ub thioester for nucleophilic attack [5]. In 
addition, some RING/U-box E3s have been shown to impose conformational 
restraints that regulate which substrate lysines can access the active site of E2~Ub 
[12, 13, 14]. In this chapter, we describe how to perform a single-turnover lysine 
discharge assay in which we use SDS-PAGE to follow Ub transfer from E2~Ub to 
free lysine in solution (Fig. 3). [INSERT FIGURE 3 NEAR HERE]. This removes 
any dependency on substrate recognition and binding and facilitates analysis of the 
mechanism used by RING/U-box E3s to prime E2~Ub and promote Ub transfer. By 
using this reductionist approach combined with mutagenesis, we can explore the role 
of the E2 in coordinating donor Ub (the thioesterified Ub) in the presence and absence 
of E3, the role of the RING or U-box domain in coordinating donor Ub and priming 
E2~Ub for transfer, and the role of additional components in stimulating or inhibiting 
the actions of the RING or U-box domain in mediating Ub transfer.  
 
A single-turnover lysine discharge reaction consists of a charge step in which Ub is 
loaded onto E2 by E1, a stop step in which reagents are added to inactivate E1 and 
prevent additional loading of Ub onto E2, and a final step in which lysine alone or a 
mixture of lysine with E3 and/or additional components is added to initiate discharge 
of E2~Ub (Fig. 3). Each step requires empirical optimization. E2-charging efficiency 
depends on the E1-E2 pair and can be influenced by a number of factors including 
changing the duration and/or temperature of the charging step, the source organism 
for E1, and relative concentrations of E1, E2 and Ub. In most cases, adding EDTA 
quenches the charge reaction. However, for some E1-E2 pairs, inclusion of apyrase 
together with EDTA seems to work more effectively. For a clear, visually convincing 
result, the disappearance of the E2~Ub band should be readily apparent over the time 
points selected and can be affected by adjusting factors like the concentration of 
lysine and/or E3, or running the assay at a different temperature for the discharge 
step. 
 
We routinely use Arabidopsis thaliana Uba1 as our E1, human UbcH5B as our E2 
and radiolabeled Ub (32P-Ub). We have devised a method to purify relatively large 
quantities of active Arabidopsis Uba1 from E. coli compared to other species [15] and 
found it to be fairly robust with respect to storage, handling, and E2-charging 
efficiency. We use UbcH5B when possible/relevant because almost 100% of UbcH5B 
can be loaded with Ub in our charge reaction. Additionally, most RING/U-box E3s 
react with UbcH5B~Ub and substrate lysine modification is fairly promiscuous with 
this E2 in vitro [16]. In cases where we want to avoid stimulation of Ub transfer by 
non-covalent binding of Ub to the surface of UbcH5B opposite the active site Cys 
[17, 18], we use an S22R substitution on UbcH5B. Although lysine discharge assays 
can be performed using Coomassie staining alone, radiolabeled assays are more 
sensitive and prevent detection/interpretation problems that arise due to overlapping 
bands on a gel, whether these bands arise from similarly sized assay components or 
contaminants. Other methods like fluorescent labeling of Ub are also suitable but the 
labeling and detection processes require additional optimization and/or 
standardization such as what fraction of Ub requires labeling to obtain a detectable 
signal, how stable is the label, and how much gel-to-gel variation is present. Hence, 
when possible, we use 32P-Ub in our assays. 
 
In the following method, we describe the procedure used to scout for suitable lysine 
discharge conditions to investigate Ub transfer mediated by the RING domain of 
RNF38 (RNF38RING, residue 389–C). “Suitable conditions” for these assays depend 
on the type of comparison being made. Previously, to demonstrate that RNF38RING-
mediated Ub transfer proceeded via the same general mechanism as other RING E3s, 
we introduced mutations into RNF38RING, UbcH5B or Ub and investigated their effect 
on lysine discharge reactions compared to wild-type [18]. For this type of comparison 
in which the mutations are expected to slow discharge, “suitable conditions” involve 
lysine/E3 concentrations and a time frame where UbcH5B~Ub is discharged within 
the first few time points. In contrast, when we used RNF38RING to demonstrate that 
non-covalent binding of Ub to UbcH5B stimulates E3-mediated Ub transfer, the 
lysine/E3 concentrations and time frame were adjusted so that UbcH5B~Ub was 
incomplete at the later time points in the absence of excess non-covalent Ub. 
 
 
2. Materials 
Prepare all solutions with ultrapure water. Purification protocols for Arabidopsis E1, 
2TK-Ub (see Note 1), UbcH5B, and RNF38RING are available in the indicated 
references [15, 18]. 
 
2.1 Preparation of buffers and solutions. 
1. 5 M NaCl. 
2. 1 M Tris-HCl, adjusted to pH 7.6. 
3. 2 M MgCl2. 
4. 1 M NaOH. 
5. 0.5 M ATP, adjusted to pH 7-8 with NaOH and stored at -20 °C in 100 L 
aliquots. 
6. 10x Charge Buffer: 500 mM Tris-HCl, pH 7.6, 50 mM ATP, 50 mM MgCl2. 
When mixing the buffer, MgCl2 is added after all the other components 
including water to avoid producing an insoluble Mg-ATP complex. This 
buffer is prepared fresh weekly and stored at 4 °C. 
7. 1.5 M L-lysine, pH 7.6: Add 2.46 g L-lysine monohydrate (Formedium) to ~4-
5 mL water, adjust pH to 7.6 with NaOH and then add water to a final volume 
of 10 mL. This solution is stored in 0.5-1 mL aliquots at -20 °C and can be 
repeatedly frozen and thawed. 
8. TBS buffer: 150 mM NaCl, 25 mM Tris-HCl, pH 7.6.  
9. 0.5 M EDTA, pH 8.0. 
10. 1 U/L Apyrase (Sigma A6535) solubilized in a buffer containing 50 mM 
NaCl, 25 mM HEPES, pH 7.0, 1 mM MgCl2, and 1 mM DTT. Snap freeze in 
liquid nitrogen and store at -80 °C in 5-10 L aliquots. Each aliquot is thawed 
only once and used fresh on the day of the experiment. 
11. 20 mg/mL BSA (Sigma A3294) in water. Store at -20 °C in 200 L aliquots. 
Can be repeatedly frozen and thawed. 
12. 10x -32P-ATP labeling buffer: 1 M NaCl, 150 mM Tris-HCl, pH 7.6, 120 mM 
MgCl2, 10 mM DTT. Store at -20 °C in 100 L aliquots and re-frozen/thawed 
as needed. 
 
2.2 Sample preparation and analysis. 
1. 1.5 mL Eppendorf tubes. 
2. NuPAGE 4-12% Bis Tris gels (Invitrogen Thermo Fisher Scientific) or similar 
3. 4x NuPAGE LDS sample buffer (Invitrogen Thermo Fisher Scientific) 
4. 2x SDS-PAGE sample buffer (non-reducing): Equal volumes of non-reducing 
4x NuPAGE LDS sample buffer and water. 
5. 1x MES Running buffer: 50 mM MES, 50 mM Tris-HCl, pH 7.3, 0.1 % SDS, 
1 mM EDTA (in our case, prepared from a 20x solution purchased from 
Invitrogen Thermo Fisher Scientific). 
6. Plastic containers with dimensions suitable to accommodate the gel.  
7. Fixing/gel drying buffer: 5% methanol, 8% acetic acid, 5 % glycerol. 
8. Whatman paper, cut into pieces slightly bigger than gel. 
9. Whatman paper, cut to the size of the gel dryer. 
10. Gel dryer. 
11. Film or phosphor storage cassette. 
12. Film developer or phosphor imager. 
 
3. Methods 
3.1 Preparation of 100 M radioactively labeled 32P-Ub (see Note 2).  
1. Calculate the volume of 2TK-Ub (see Note 1) to achieve a concentration of 
100 M Ub in 200 L labeling buffer. This volume is 2.9 L based on our 
current 2TK-Ub stock concentration of 6.96 mM. 
2. Mix 20L 10x -32P-ATP labeling buffer with 169.9 L water, 2.9 L 2TK-
Ub, 6.2 L -32P-ATP (6000 Ci/mmol 10 mCi/mL), and 1 L of cAMP-
dependent Protein Kinase, catalytic subunit (NEB P6000L). Incubate at room 
temperature for 1-4 hours. Store at 4 °C. 
 
3.2 Preparation of lysine discharge solutions.  
Prepare discharge solution(s) just prior to running assays. With the exception of BSA 
(see Note 3), the concentration of lysine, E3 and/or additional components should be 
twice the final desired concentration (see Note 4). The stability of the E3 and any 
additional components will determine the concentrations of NaCl, buffer and DTT 
required in the discharge solution. For RNF38RING, NaCl and buffer (Tris-HCl, pH 
7.6) concentrations can range between 50-150 mM and 10-50 mM, respectively, and 
no DTT is required.  
1. Lysine dilution buffer/lysine-only discharge buffer: 20 mM lysine, 1 mg/mL 
BSA, 50 mM NaCl, 25 mM Tris-HCl, pH 7.6 (200 L). 
2. Lysine/E3 discharge solution: 20 mM lysine, 1 mg/mL BSA, 800 nM 
RNF38RING (100 L, see Note 5).  
 
3.3 Preparation of stop solution.  
Stop solution should be prepared just prior to running assays (See Note 6). 
1. Stop solution: 250 mM NaCl, 500 mM Tris-HCl, pH 7.6, 150 mM EDTA, and 
0.1 U/L apyrase. After charging and stopping, a reaction contains 0.5 units of 
apyrase for every 0.1 mol of ATP.   
 
3.4 Preparation of charge stock solution. 
Charge stock solution should be prepared just prior to running assays. 
1. Per 25 L charge reaction: 1x charge buffer, 12.5 M UbcH5B, 12.5 M 32P-
Ub (see Note 7), ~75-100 mM NaCl, minimal amounts of reducing agent , i.e. 
only what is carried over from stock solutions. (see Note 8).  
2. Calculate the volume of each reagent required per reaction. The relative 
amounts of water and TBS buffer will vary depending on the stock 
concentrations of E1, E2 and 32P-Ub and the NaCl content of each of these 
solutions. For these assays, both the stocks of UbcH5B and 32P-Ub are at 100 
M and contain 150 mM NaCl. The stock of Arabidopsis E1 is at 30 M and 
contains ~200 mM NaCl. In this case, the volume required to bring the 
solution to 25 L can be split equally between water and TBS buffer. If one of 
the components is very dilute or very concentrated, then the ratio will need 
adjusting. Each 25 L reaction requires 2.5 L 10x charge buffer, 3.125 L 
100 M UbcH5B, 3.125 L 100 M 32P-Ub, 0.833 L 30 M Arabidopsis 
Uba1, 1.25 L BSA (20 mg/mL), 7.1 L water, and 7.1 L TBS buffer.  
3. There are six reactions in total (see below), but the stock volume is calculated 
based on eight to account for handling errors. Mix the components in the 
following order:  
a. 20 L 10x Charge Buffer. 
b. 56.8 L water. 
c. 56.8 L TBS buffer. 
d. 10 L BSA (20 mg/mL). 
e. 25 L 100 M UbcH5B. 
f. 6.7 L 30 M Arabidopsis Uba1 (See Note 9). 
4. Flick tube and microfuge briefly (~10 sec). Add 21.9 L to each of six 
Eppendorf tubes. 
 
3.5 Assay assembly and execution.  
1. Prepare sample tubes. Based on an assay with five time points including a zero 
time point (T0), each assay requires 25 L of a charged E2~Ub solution, 6.125 
L of a stop solution and 30 L of a discharge solution. 
2. Add 6 L 2x SDS-PAGE sample buffer to Eppendorf tubes for T0 for each 
reaction. Make sure there is no reducing agent in the sample buffer. 
3. Add 4 L of 4x sample buffer to the tubes for assay time points following 
addition of discharge solution. For the assays described here, four time points 
are taken per reaction. 
4. Dilute 30 L of lysine/E3 discharge solution from 3.2.1 with 30 L of lysine 
dilution buffer prepared in step 3.2.2. 
5. Dilute 30 L of lysine/E3 discharge solution from step 4 with 30 L of lysine 
dilution buffer prepared in step 3.2.1. Repeat 2-fold E3/lysine discharge buffer 
serial dilution a total of four times. The discharge solutions for the reactions 
are as follows: 
a. Reaction 1: 20 mM lysine, 1 mg/mL BSA. 
b. Reaction 2: 20 mM lysine, 800 nM RNF38RING, 1 mg/mL BSA.  
c. Reaction 3: 20 mM lysine, 400 nM RNF38RING, 1 mg/mL BSA. 
d. Reaction 4: 20 mM lysine, 200 nM RNF38RING, 1 mg/mL BSA. 
e. Reaction 5: 20 mM lysine, 100 nM RNF38RING, 1 mg/mL BSA. 
f. Reaction 6: 20 mM lysine, 50 nM RNF38RING, 1 mg/mL BSA. 
6. Add 3.125 L 100 M 32P-Ub to 21.9 L charge stock aliquoted in step 
3.4.4. Start the timer. 
7. Flick tube to mix and spin down briefly (~5 sec) in a benchtop mini 
centrifuge.  
8. Incubate for 15 minutes (See Note 10). 
9. Add 6.125 L stop solution. Flick the tube to mix and spin down briefly (~5 
sec) in a benchtop mini centrifuge (See Note 11).  
10. About 15-30 sec after adding stop solution, remove 6 L and add to T0 sample 
tube and vortex. (See Note 12).  
11. About 1-2 min after adding stop solution, add 25.125 L discharge solution 
from step 3.5.5. Pipette up and down 5-10 times. 
12. Flick the tube to mix and spin down briefly (~5 sec) in a benchtop mini 
centrifuge.  
13. Take 12 L time points at 30, 60, 90 and 120 seconds after adding discharge 
solution for each reaction. Vortex immediately upon adding to gel sample 
buffer. (See Note 13). 
14. Microfuge all samples for ~15 seconds prior to loading onto SDS-PAGE gels 
(See Notes 14 and 15).  
15. Load samples onto SDS-PAGE gels by reaction with T0 followed by the time 
course. Use non-reducing buffers when running gels. 
16. Run gels at 200 V for approximately 35 minutes so that the 32P-Ub band 
almost reaches the bottom of the gel.  
17. Transfer the gels to plastic containers filled with fixing/gel drying buffer. Trim 
off the foot and most of the stacker, leaving ~3 mm of each well. Leave in 
buffer for 2-5 minutes. 
18. Prepare a stack of at least three pieces of gel-sized Whatman filter paper. 
Label top piece with a unique gel identifier. 
19. Pre-wet the labeled filter paper in fixing/gel drying buffer and return to top of 
stack. Place gel on the labeled filter paper.   
20. Place gel stack on three pieces of Whatman filter paper that are cut to a size 
slightly smaller than your gel dryer. 
21. Dry gels. We use cling film to avoid contaminating the gel-drying equipment 
with radioactive material. 
22. Expose gels to film in a darkroom or a phosphor storage cassette to capture the 
signal from 32P-Ub. Try different exposure times to ensure an optimal and 
accurate visual representation of the results (See Notes 16 and 17). The 
exposure time is dependent upon the concentration of the radioactive material 
and the age of the 32P used (half-life is about 14 days).  
23. Analyze results based upon the disappearance of the E2~Ub band over time 
(see Figure 4) to determine if a suitable condition has been found or further 
screening is required. 
[INSERT FIGURE 4 NEAR HERE] 
 
Notes 
1. Labeling in our experiment relies on a 2TK tag (RRASV) at the N-terminus of 
Ub. The gene encoding Ub has been cloned into the BamHI and EcoRI sites of 
a modified pGEX-2TK GST expression vector (GE Healthcare) in which the 
thrombin cleavage site has been replaced with TEV and a non-cleavable His6 
tag precedes the GST tag.  
2. The final labeled concentration of 2TK-Ub and amount of -32P-ATP can be 
varied. 
3. Some E3s adhere to the surface of the Eppendorf tubes, which reduces 
apparent activity and affects assay reproducibility. When possible, BSA is 
added to discharge solutions prior to adding E3 or additional protein/peptide 
components to prevent adherence.  
4. Although we do not fit kinetic parameters with lysine discharge assays, the 
concentrations of various reactants are determined as if a kinetic analyses were 
intended. Under ideal conditions, the maximum concentration of E3 (the 
enzyme) used in any reaction is at least ten-fold lower than E2~Ub (the 
substrate). 
5. Protein stocks are stored at -80 °C at a minimum concentration of 1 mg/mL.  
Diluted working E3 stocks are prepared in TBS containing 1 mg/mL BSA to 
minimize losses from surface adherence. For the discharge assays presented 
here, the -80 °C stock of RNF38RING was at 8.7 mg/mL (937 M). A 5 M 
working stock in TBS containing 1 mg/mL BSA was prepared to make the 
discharge solution. 
6. Although apyrase is inhibited by EDTA, we have found that using a 
combination of the two is slightly more effective at stopping charging for 
certain E1-E2 pairs. The concentrations of the other reagents in the stop 
solution are unchanged regardless of whether apyrase is used. 
7. When using a new E2, initial experiments needs to be done to characterize the 
level of ubiquitin charging onto E2 that can be achieved with a given E1. An 
ideal charge reaction will convert all the E2 to E2~Ub without producing 
byproducts like diUb, E2–Ub or E1–Ub, where – denotes an isopeptide bond 
between the C-terminal diglycine motif of Ub and the side chain of a lysine 
residue on the protein. The species of origin of the E1 plays a significant role 
in the E2-conjugating efficiency as well as the duration, temperature of the 
charge reaction, and molar ratio of 32P-Ub to E2. For a given E2, we optimize 
charging conditions by using SDS-PAGE to analyze time courses of several 
charge reactions in which 32P-Ub:E2:E1  ratios are varied.  Almost all of 
UbcH5B can reliably be converted to UbcH5B~Ub up to concentrations of 20 
M UbcH5B using molar ratios of 32P-Ub:UbcH5B between 1:1 and 2:1 with 
1 M Arabidopsis E1.  
8. Because the E2~Ub thioester is labile, it is important that the concentration of 
reducing agent is kept to a minimum.  
9. At concentrations less than ~100 nM, there is a pronounced reduction in Uba1 
activity due to surface adherence. Hence, when possible, BSA is included in 
the charge reaction and Uba1 is added after BSA. If BSA is not used, Uba1 is 
always added after E2.   
10. Ub mutants can influence the rate of the E1-E2 transthiolation reaction. In 
reference [15], some charge reactions with Ub mutants were run for 30 
minutes instead of 15 minutes to produce equivalent amounts of E2~Ub to the 
corresponding wild-type reaction. 
11. Stopping the reaction is critical. New E1-E2 combinations should be tested by 
setting up a charge reaction, adding the stop solution, and collecting samples 
over 10 minutes to check that the reaction has stopped charging and to 
investigate the stability of E2~Ub. For UbcH5B, once the charge reaction is 
stopped, a reduction in UbcH5B~Ub is evident in as little as 5 minutes.   
12. For each reaction in an assay, the time between adding stop, removing T0 and 
adding discharge solution should be the same and kept to a minimum. 
13. Thioester bonds are labile at higher temperature, so do NOT boil the samples. 
14. The viscosity of the gel sample buffer from Invitrogen frequently causes 
problems with reproducibly pipetting accurate volumes. Hence, all the sample 
volume for each time point is loaded onto the gel.   
15. Because of the labile nature of E2~Ub, samples are sensitive to discharge even 
after denaturation with gel loading buffer. Hence, gels should be run promptly 
after completing an assay and there are no benefits to holding back “extra” 
sample in the event that there is a problem with a gel. In addition, when 
running multiple reactions in an assay, it is best to stagger the reactions to 
minimize the time between completing the first reaction and loading the gels. 
16. When working with new systems, overexposure to check for byproducts is 
advised to ensure that the concentration of lysine is saturating under the 
conditions tested. When working with a new system, films should be exposed 
for a long time to check that Ub transfer occurs to free lysine and not lysine 
residues on the surface of any of the proteins in the system. We have 
previously observed formation of diUb and E3–Ub (where – indicates an 
isopeptide linkage) when lysine concentrations were too low. 
17. When multiple gels are run to compare reactions in an assay, the gels should 
be exposed to film at the same time and onto the same film. 
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Figure captions 
 
Figure 1: Schematic overview of the ubiquitination cascade. (a) Ub is activated by E1 
and (b) transferred to E2 conjugating enzyme. (c) E3 ligase mediates the transfer of 
Ub from E2~Ub, onto substrate. (d) Close up of final isopeptide bond between Gly 76 
of Ub and a Lys sidechain on substrate. (e) RING E3 recruits E2~Ub and substrate to 
facilitate direct transfer of Ub from E2 onto the substrate.   
 
Figure 2: Enzymatic mechanism of substrate ubiquitination by RING/U-box E3 
ligases. (a) RING/U-box E3 ligases recruit substrate and E2~Ub, thereby forming a 
RING/U-box-substrate-E2~Ub complex; spatial restraints imposed by the E3 
frequently play a key role in substrate lysine selectivity. (b) A residue from the E2 
(D117 in UbcH5B) deprotonates the lysine side chain amine, thereby converting it to 
a nucleophile. (c) This nucleophile attacks the carbonyl of the E2~Ub thioester, 
forming an oxyanion intermediate in which covalent interactions are present between 
substrate, the catalytic Cys of E2 (C85 in UbcH5B) and Ub. The oxyanion 
intermediate is stabilized by N77 in UbcH5B. (d) Deprotonation of the intermediate, 
which may be performed by a residue from the E2, followed by (e) elimination of a 
thiol, (f) thereby freeing the catalytic Cys of E2 to accept another Ub and producing 
an isopeptide bond between the side chain of a substrate lysine and Gly 76 of Ub. 
MarvinSketch was used for drawing chemical structures and reactions [19]. 
 
Figure 3: Schematic overview a lysine discharge reaction. (a) Charge: E1, E2 and Ub 
are mixed to produce E2~Ub; (b) Stop: Chemical and/or enzymatic reagents are 
added to inactivate E1, thereby preventing production of more E2~Ub or recharging 
of the E2 after discharge; (c) Discharge: L-lysine, E3 and/or additional components 
are added and (d) the discharge of E2~Ub over time is monitored by SDS-PAGE. 
 
Figure 4: Non-reduced autoradiograms of reactions 1–6 as described in the methods 
section showing the discharge of UbcH5B~32P-Ub over 2 min with final 
concentrations of 10 mM L-lysine and 0-400 nM RNF38RING as indicated. For assays 
in which comparisons are made with a stimulating component like non-covalent Ub 
[18], 25-50 nM RNF38RING and 10 mM L-lysine are a suitable starting point provided 
that the stimulatory component/effect is strong enough to drive the reaction to 
completion in two minutes. For comparisons across reactions involving UbcH5B 
mutations that slow discharge, a suitable starting concentration of RNF38RING would 
be between 200-400 nM, depending on the extent that mutants disrupt discharge. A 
possible next step in the optimization process would be to test a narrower 
concentration range of RNF38RING with a mutation that abolishes E3-mediated 
discharge. 
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